Merck received FDA approval for Lipfendra, the first oral PCSK9 inhibitor, expanding the cholesterol-lowering toolkit beyond injectable agents. The macrocyclic peptide is designed for oral formulation and targets the PCSK9 pathway that helps regulate LDL cholesterol. For patients with high cholesterol who require additional LDL lowering, the approval changes the administration profile of PCSK9 therapy. It also raises the competitive bar for next-generation lipid drugs focused on convenience without sacrificing potency. The move highlights continued FDA openness to non-traditional formats within established drug classes, including peptide therapeutics engineered for oral delivery.